Liu Lidong, Guo Kai, Yang Dayong
Department of Ophthalmology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Department of Neurology, Mayo Clinic, Rochester, MN, United States.
Front Neurol. 2025 May 6;16:1559172. doi: 10.3389/fneur.2025.1559172. eCollection 2025.
Optic neuritis (ON) and neuromyelitis optica spectrum disorders (NMOSD) are inflammatory neuro-ophthalmological conditions characterized by significant visual impairment and diverse clinical manifestations. Advances in diagnostic biomarkers have improved disease identification, including aquaporin-4 immunoglobulin G (AQP4-IgG) and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG). However, some patients remain biomarker-negative, complicating differential diagnosis and personalized treatment. Multi-omics approaches have provided valuable insights into critical molecular pathways, novel biomarkers, and the shared and distinct features of ON and NMOSD. This review highlights recent advancements in biomarker research for ON and NMOSD, emphasizes the potential of multi-omics integration, identifies existing challenges, and proposes future research directions. These findings aim to enhance diagnostic accuracy, improve prognostic capabilities, and support the development of precision medicine strategies for ON and NMOSD.
视神经炎(ON)和视神经脊髓炎谱系障碍(NMOSD)是炎症性神经眼科疾病,其特征为严重视力损害和多样的临床表现。诊断生物标志物的进展改善了疾病识别,包括水通道蛋白4免疫球蛋白G(AQP4-IgG)和髓鞘少突胶质细胞糖蛋白免疫球蛋白G(MOG-IgG)。然而,一些患者生物标志物呈阴性,这使得鉴别诊断和个性化治疗变得复杂。多组学方法为关键分子途径、新型生物标志物以及ON和NMOSD的共同和独特特征提供了有价值的见解。本综述强调了ON和NMOSD生物标志物研究的最新进展,强调了多组学整合的潜力,识别了现有挑战,并提出了未来的研究方向。这些发现旨在提高诊断准确性、改善预后能力,并支持ON和NMOSD精准医学策略的发展。